Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

Published:2023-10 Issue: Volume:64 Page:102240
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Xu Bushu,Pan Qiuzhong,Pan Hua,Li Haomiao,Li Xianan,Chen Jing,Pang Danmei,Zhang Baoqing,Weng Desheng,Peng Ruiqing,Fang Meiyu,Zhang Xing

Publisher

Elsevier BV

Subject

General Medicine

Reference49 articles.

1. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine;Gamboa;CA Cancer J Clin,2020

2. The 2020 WHO classification of soft tissue tumours: news and perspectives;Sbaraglia;Pathologica,2021

3. Trends in survival for patients with metastatic soft-tissue sarcoma;Italiano;Cancer,2011

4. Soft tissue sarcomas;Cormier;CA Cancer J Clin,2004

5. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group;Santoro;J Clin Oncol,1995

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Benefit assessment of novel systemic therapies for bone and soft tissue sarcomas: a cross-sectional study;Japanese Journal of Clinical Oncology;2024-07-31

3. Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis;Frontiers in Oncology;2024-05-14

4. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection;Cancers;2024-01-08

5. Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma;Therapeutic Advances in Medical Oncology;2024-01